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Abstract 
Drugs on the market continuously improve and target directed drugs become more 
and more common. Animal models are used to predict effects and side effects that 
may occur when drugs are administered to humans. The use of mice within medical 
testing is steadily increasing and the use of transgenic mouse models is also 
expanding. In this thesis, both traditional mouse strains, and a humanized 
CYP2C18/CYP2C19 transgenic mouse model is investigated. 
Initially, we found that cytochrome P450 (CYP) enzymes in the liver of 
traditional mouse strains are expressed with large strain and sex differences in both 
protein levels and metabolic activity. These differences contribute to the difficulties 
when extrapolating data to man from tests performed on animals. 
The CYP2C18/CYP2C19 transgenic mouse model investigated contains, in 
addition to the murine Cyp2c enzymes, the human CYP2C18 and CYP2C19 
enzymes. Heterozygous CYP2C18/CYP2C19 transgenic mice were healthy 
animals, without obvious adverse phenotypic characteristics and were determined to 
possess approximately 12 tandem copies of the inserted CYP2C18/CYP2C19 gene 
segment. The inserted gene was translated into CYP2C18 and CYP2C19 mRNA 
and CYP2C19 protein more efficiently in male than in female mice livers, whereas 
no sex differences were found in small intestine, lung or brain. The enzymatic 
activity of CYP2C19 is also higher in males than in females. 
The sexually dimorphic, male predominant, CYP2C18 and CYP2C19 gene 
expressions, as well as the expression of female predominant, endogenous, mouse 
Cyp2c37, Cyp2c38, Cyp2c39 and Cyp2c40 genes were found to be dependent on 
androgens and the release pattern of growth hormone. 
In summary, large strain– and sex differences in CYP expression occur in mice. 
Sex differences in expression of CYP2C18 and CYP2C19 are evident in a 
transgenic mouse model containing human CYP2C18 and CYP2C19 genes. The 
sex dependent differences in expression are affected by gonadal hormones and 
growth hormone. The transgenic mouse model, may serve as a model for 
investigation of human CYP2C18 and CYP2C19 gene regulation. 
Keywords: mouse, CYP2C, liver, transgenic, gender, sex, dimorphic, mRNA, 
protein, metabolism 
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  7  8Abbreviations 
7-EFC 7-ethoxy-4-trifluoromethyl  coumarin 
ACN acetonitrile 
ATP adenosine  triphosphate 
BAC  bacterial artificial clone 
BSA  bovine serum albumin 
CAR  constitutive androstane receptor 
CAR-RE constitutive  androstane receptor-responsive element 
cDNA complementary  DNA 
CYP cytochrome  P450 
DAPI 4’,  6-diamidino-2-phenylindole 
DNA deoxyribonucleic  acid 
dUTP 2'-Deoxyuridine  5'-Triphosphate 
ECL enhanced  chemiluminescence 
EMSA  electrophoretic mobility shift assay 
EROD 7-ethoxyresorufin  O-deethylation 
ES cells  embryonic stem cells 
FAM 6-carboxyfluorescein 
GAPDH glyceralaldehyde-3-phosphatedehydrogenase 
gDNA genomic  DNA 
GH growth  hormone 
HAc acetic  acid 
HE  haematoxylin and eosin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic  acid 
HNF  hepatocyte nuclear factor 
HPLC  high-performance liquid chromatography 
HPRT hypoxanthine  guanine  phosphoribosyltransferase 
HRP horseradish  peroxidase 
IL-2 Interleukin-2 
  9LC liquid  chromatography 
mRNA messenger  RNA 
MS mass  spectrometry 
MS/MS  tandem mass spectrometry 
NADPH  nicotinamide adenine dinucleotide phosphate, reduced form 
PAGE  polyacrylamide gel electrophoresis 
pH  negative logarithm of the hydrogen ion concentration of an 
aqueous solution 
Poly (dI-dC)-
Poly (dI-dC) 
polydeoxyinosinic-deoxycytidylic acid 
PVDF polyvinylidene  fluorid 
PXR  pregnane X receptor 
RNA ribonucleic  acid 
rtPCR  reverse transcription polymerase chain reaction 
SDS  sodium dodecyl sulphate 
STAT5b  signal transducer and activator of transcription 5b 
SYBR Green  an asymmetrical cyanine dye used as nucleic acid stain 
TBS tris-buffered  saline 
UV ultraviolet 
VIS visible 
YAC  yeast artificial clone 
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Background 
Available drugs continuously improve- and with medical treatments today 
we can cure previously untreatable and fatal diseases. Analytical methods 
develop and target-directed drugs become more and more common. 
However, knowledge about factors influencing the fate of the administered 
drugs in the body is essential to avoid undesired and toxic effects. Adverse 
effects are not always dose dependent; they may depend on the patients’ 
diet, drinking- and smoking habits as well as interactions with other drugs. 
Polymorphism in the cytochrome P450 (CYP) system may also give 
unexpected and toxic effects. 
 
In modern drug development, animal models are used to predict drug 
kinetics and toxicity in humans. Interpretation of the results and 
extrapolations to man of data from studies performed on animals may be 
difficult due to broad interspecies and interindividual variations among 
cytochrome P450 enzymes (Gonzalez, 1990). Different species may express 
different levels of related enzymes/subfamilies and these differences can give 
rise to species specific toxic effects. Differences in expression of CYP 
enzymes have been observed between genders (Kato & Yamazoe, 1992; 
Werner et al., 1995), and expression may also vary with age (Wauthier et al., 
2007). It is therefore important to take CYP enzyme differences into 
consideration when using animal species as models to predict kinetics and 
toxicity in humans (Pearce et al., 1992). 
 
Over recent years, more and more experiments have been performed in 
mice, which are used both as disease models and for drug safety testing. 
  11Mice, like other species, have evolved complex mechanisms for 
metabolizing compounds and other molecules that enter the body. 
Innoxious molecules should be put to some use and toxic compounds 
should be neutralized. The means to accomplish this has been solved in 
slightly different ways in different species and strains. Despite the growing 
use of mice, relatively few studies have been performed to examine specific 
reactions catalyzed by different mouse CYP isoforms and their relevance to 
humans. When extrapolating data from mouse models to humans, it is 
important to compare the drug metabolism of mouse to that of humans 
(Perloff et al., 2000). 
 
Optimized animal models where expected (and unexpected) human 
pathology is mimicked and where pathogenic biological effects are identified 
are desirable to predict adverse compound effects in humans. Expectations 
have risen that humanized mice will work as tools to accomplish more 
predictive animal models. 
 
Elimination of drugs from the body is accomplished by metabolism of the 
drug, usually to a more water-soluble state, and finally by excretion. How 
quickly the drug is eliminated from the body is highly dependent on the rate 
with which the compound is metabolized. The rate of the transformation 
affects the concentration of the compound in different organs as well as how 
long the drug stays in the body. The cytochrome P450 system in the liver is 
central in oxidation of a wide variety of structurally unrelated compounds, 
including exogenous compounds such as pharmaceutical agents, chemicals 
and other lipophilic xenobiotics, as well as endogenous steroids, fatty acids, 
prostaglandins and vitamin D3 (Bièche et al., 2007; Gonzalez, 1990; Ryan & 
Levin, 1990). However, CYP enzymes are also expressed in other tissues 
(Bièche et al., 2007). 
Drug metabolising enzymes 
The metabolism and elimination of xenobiotic compounds is traditionally 
divided into two phases. The so-called Phase I is usually effected by P450 
monooxygenases, also called cytochrome P450s (CYPs) or mixed-function 
oxidases. The most common primary outcome of Phase I activity is the 
addition of one atom of oxygen to the substrate, although many other 
reactions  are also  catalyzed  by  cytochrome  P450  enzymes (Isin & 
Guengerich, 2007). The metabolites formed by the Phase I reactions are 
generally more hydrophilic than the parent compound. Furthermore, the 
  12insertion of an oxygen atom into the parent molecule allows the resulting 
metabolites to easier undergo other metabolic transformations, known as 
Phase II, or conjugation reactions. Phase II reactions are enzymatic reactions 
that covalently link an endogenous compound to the product derived from 
the cytochrome P450 oxidation. Such conjugates are usually water-soluble, 
and therefore easily excreted in either bile or urine (Kyle & Farber, 1991). 
 
The combination of Phase I and Phase II metabolism converts lipophilic 
xenobiotics into forms that can readily be excreted from the body, hence 
this metabolism promotes elimination of compounds that would ultimately 
prove toxic if allowed to accumulate in the body. For this reason, oxidation 
is widely regarded as a detoxifying mechanism. However, there is little 
doubt that CYP dependent oxidation can also convert some foreign 
compounds into reactive metabolites. The biotransformation sometimes 
produces species that are clearly more toxic, mutagenic or carcinogenic than 
the original substrate (Kyle & Farber, 1991). Furthermore, extensive and 
variable biotransformation by cytochrome P450s can sometimes result in the 
formation of one or more metabolites with pharmacological activity, which 
may be equal to, or even higher than that of the parent drug (Schellens et al., 
2000). 
Cytochrome P450 
The CYP enzymes are heme containing, membrane bound proteins. The 
original term cytochrome P450 was coined at the time when the protein 
was given its provisional name (Omura & Sato, 1962). The figure, 450, 
originates from the peak absorbance at 450 nm. The drug metabolizing 
CYPs are commonly localized in the membranes of the smooth 
endoplasmatic reticulum, but mitochondrial (Omura, 2006) and nuclear 
activities (Madra et al., 1996) have also been described. However, the drug 
metabolizing activities of the last two compartments are low compared to 
that of the system in the endoplasmatic reticulum. 
 
To be enzymatically active, the CYPs require oxygen and a supply of 
electrons. The first electron is derived from NADPH via an accessory 
flavoprotein (NADPH cytochrome P450 reductase). Either NADPH 
cytochrome P450 reductase or cytochrome b5 donates a second electron to 
yield a reduced complex with two electrons (Guengerich, 2001). The 
reductive activation of oxygen is followed by cleavage of the oxygen-
  13oxygen bonds. One atom of oxygen is transferred to the substrate, while the 
other atom is incorporated into water. 
 
The members of the P450 superfamily are divided into families, subfamilies 
and individual members. Members within a gene family have >40% 
homologous amino acid sequence, and the families are enumerated with 
Arabic numbers. Members within a subfamily share >55% of their amino 
acid sequences, and are grouped with Latin letters (Gonzalez, 1990). Finally, 
the individual isoforms are identified by again using Arabic numbers (Nelson 
et al., 1996). 
 
There are three main cytochrome P450 gene families involved in drug 
metabolism in the human liver, namely CYP1, CYP2 and CYP3 (Rang et 
al., 1999). These families are also important in many extrahepatic tissues 
including lung, kidney, heart, brain, gut and nasal epithelium (Jeffery, 1991). 
Cytochrome P450-CYP2C family 
In humans the CYP2C family has four members, namely CYP2C8, 
CYP2C9, CYP2C18 and CYP2C19 (Goldstein, 2001), and they contribute 
to biotransformation of about 30% of all drugs in the liver (Guengerich, 
2003). Despite the >80% amino acid sequence identity shared by CYP2C8, 
9, 18, and 19, considerable differences in substrate specificity exist between 
them. Diclofenac, tolbutamide, and S-warfarin are typical CYP2C9 
substrates, and S-mephenytoin and R-omeprazole are characteristic 
substrates for CYP2C19. CYP2C8 metabolizes a few known drugs such as 
paclitaxel, troglitazone, and zopiclone (Goldstein & de Morais, 1994; 
Pelkonen  et al., 1998). CYP2C8 and CYP2C9 are also involved in the 
endogenous metabolism of arachidonic acid (Rifkind et al., 1995; Daikh et 
al., 1994). To date, no CYP2C18 protein or drug substrate has been found 
in vivo (Läpple et al., 2003). 
 
The mouse Cyp2c subfamily is one of the largest and most
 complex in 
the cytochrome P450 super family and contains 15 genes and four 
pseudogenes (Figure 1) all located to chromosome 19 (for an update, see 
http://drnelson.utmem.edu/CytochromeP450.html). Cyp2c29 was the first 
mouse Cyp2c member identified (Matsunaga et al., 1994), followed by 
Cyp2c37, Cyp2c38, Cyp2c39, and Cyp2c40 (Luo et al., 1998). Thereafter, 
ten more mouse Cyps have been found, namely Cyp2c44 (DeLozier et al., 
  142004), Cyp2c50, Cyp2c54 Cyp2c55 (Stewart & Strother, 1999) and 
Cyp2c65-70 (Nelson et al., 2004; Stewart & Strother, 1999). 
 
Figure 1. Mouse Cyp2c locus on chromosome 19. Genes are marked with green arrows, 
while pseudogenes are marked with apricot arrows. Cyp2c44 is located 3.8Mb downstream 
from the main Cyp2c cluster (1.5Mb). 
 
The mouse Cyp2c: s differ in their tissue distribution and catalytic 
function (Luo et al., 1998; Tsao et al., 2000; Tsao et al., 2001; DeLozier et 
al., 2004; Stewart & Strother, 1999) but many of the mouse Cyp2c 
isoenzymes metabolize the same substrates, like arachidonic acid, but to 
different regio- and stereo specific products. 
Transgenic mice 
An important step in the development of transgenic mice was reached by 
Rudolf Jaenisch in 1974 (Jaenisch & Mintz, 1974). Viral DNA was 
successfully inserted into mouse blastocysts (preimplantation embryos) and 
the inserted DNA persisted to adult life. Another important milestone was 
when Gordon in 1981 injected foreign DNA into mouse pronuclei (Gordon 
& Ruddle, 1981). The genetic material was successfully integrated into the 
genomes of the newborn mice, and maintained through further 
development to adulthood. Thereafter, it would just take one more year 
until expression of inserted DNA segments were shown (Costantini & Lacy, 
1982). 
 
Today there are two main strategies for developing transgenic mice: In 
the so-called pronuclear injection, the foreign DNA is inserted into one of 
the pronuclei (usually the male which is larger) just after fertilization of the 
egg, see Figure 2. The injected transgenic DNA tends to integrate randomly 
into the genome, and often many tandem copies of the insert are integrated 
  15head-to-tail. The resulting mouse is only partially transgenic, but if the 
transgenic cells contribute to the germ line some transgenic eggs or sperms 
will be produced and the next generation of mice will be fully transgenic 
(Voncken & Hofker, 2005). 
 
Figure 2. Pronuclear Injection 
 
The second strategy to incorporate foreign DNA is by using embryonic 
stem cells (ES cells), see Figure 3. These cells are isolated from blastocysts 
and they are pluripotent, i.e. they are undifferentiated and have the capacity 
to differentiate into any cell type when introduced into an embryo. The 
foreign DNA is introduced into the ES cells in vitro and may introduce 
randomly, but if the foreign DNA possesses DNA sequences that are 
homologous to mouse DNA a single shift of DNA may occur. In that case a 
single copy of the transgene is inserted at a specific site. The transgenic ES 
cells are injected into the blastocyst of a donor mouse and the resulting 
blastocyst is transferred into the uterus of a foster mouse. ES cells colonize 
the host embryo and often contribute to the germ line, with the result that 
some sperm carry the transgenic DNA. When these sperm fertilize a normal 
egg, a transgenic heterozygous mouse containing foreign DNA is produced 
(Voncken & Hofker, 2005). 
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Figure 3. Generation of mice using embryonic stem (ES) cells. 
Generation of mice containing the human CYP2C genes 
The cytochrome P450 transgenic mouse project within AstraZeneca was 
originally divided into two parts. The first part was to generate a mouse in 
which the human CYP2C genes were added. The second included the use 
of ES cells to target the mouse Cyp2c genes to make a mouse line devoid of 
its Cyp2c gene cluster. Ultimately, once both types of genetically modified 
mice had been generated, they would be crossbred to make a line whose 
only source of CYP2C genes were the introduced human genes. 
 
Several strategies were explored to achieve this goal and initially it was 
believed that using pronuclear microinjection to introduce a YAC (yeast 
artificial clone) spanning the complete human locus would be the best 
approach. Unfortunately a suitable YAC was not found and an alternative 
approach using a bacterial artificial clone (BAC) was suggested. However, 
the human locus is ~437kb and thus too large to be contained on a single 
BAC. The strategy adopted was therefore to identify two BACs, each 
encoding two CYP2C genes of the human cluster, and inject each of the 
two BACs separately. An attempt to include all four genes by simultaneous 
coinjections of both BACs was also performed but was unsuccessful. 
 
A BAC clone named 466J14, containing the human CYP2C18 and 
CYP2C19 genes was identified. The 5’ end of the BAC is located at 
position –5,828 bp from the start of exon 1 of CYP2C18 and the 3’ end of 
the BAC is located at position +30,869bp from the end of exon 9 of 
CYP2C19, see Figure 4. BAC DNA was prepared by digestion to release 
the desired CYP2C18 and CYP2C19 genes and the gene fragment was 
purified. The purified BAC DNA was injected into C57BL/6 eggs 
  17(pronuclear injection) and founders were identified by genotyping of DNA 
extracted from tail or ear biopsies. 
 
Figure 4. Human CYP2C locus, located to chromosome 10, and regions contained within 
BAC 466J14 and 419M21. 
 
A second BAC clone named 419M21 (Figure 4) has been used to 
generate a humanized mouse containing human CYP2C8 and CYP2C9 
genes. No knockout model devoid of the mouse CYP2C genes has been 
generated to date. 
Genetic regulation of CYP2C genes 
Endocrine cells synthesize steroid hormones, such as glucocorticoids, 
mineralocorticoids, androgens and estrogens. Once produced, they enter the 
blood stream to reach their target cells, where they diffuse through the 
cellular membrane and bind to their receptors. The receptors are located 
either in the cytoplasm or within the nucleus in an inactive state. Once the 
receptors bind their ligands (hormones), they transform into their active 
state. The activated hormone-receptor complex can effectively bind to 
DNA elements, so called hormone responsive elements and thereby regulate 
gene transcription (Tsai & O'Malley, 1994), see Figure 5. 
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Figure 5. General overview of the mechanism for nuclear receptor action. Hormone binds to 
its nuclear receptor (NR), dimerizes, and translocates to the nucleus where the NR binds to 
its specific sequence of DNA, the so-called hormone responsive element (HRE). The nuclear 
receptor DNA complex in turn recruits other proteins that are responsible for transcription of 
downstream DNA into mRNA, which is eventually translated into protein, resulting in cell 
function changes. Picture modified from http://en.wikipedia.org/wiki/Nuclear_receptors. 
 
Growth hormone (GH) is released from the pituitary gland in a sexually 
dimorphic manner. In many species, including rats (Jansson et al., 1985) and 
mice (MacLeod et al., 1991) males secrete GH in a highly pulsatile manner 
causing interpulse intervals of little or no detectable GH in plasma, while the 
female release is characterized by more frequent pulses, giving an almost 
continuous presence of GH in plasma. The GH free interval observed in 
males is required for expression of some male-specific CYPs, such as rat 
CYP2C11 (Waxman et al., 1991). Rats treated with continuous exogenous 
GH over several days abolish the expression of male-specific liver genes and 
dramatically induce female-specific genes, such as rat CYP2C12 (Thangavel 
et al., 2004).  
 
In rats, the female specific CYP2C12 gene is regulated by signal 
transducer and activator of transcription 5 (STAT5) together with 
hepatocyte nuclear factors (HNF) -4 and –6 (Sasaki et al., 1999), as well as 
HNF3α and HNF3β (Delesque-Touchard et al., 2000). The female-specific 
pattern is proposed to be stimulated by the liver enriched HNF: s and 
dominantly inhibited by the GH-activated STAT5b that is manifest in males 
(Delesque-Touchard et al., 2000). Another hypothesis is that STAT5 (and 
other transcription factors) do not have access to their target elements in 
  19male rats which causes a silencing effect of the CYP2C12 gene (Endo et al., 
2005). The expression of the GH-pulse inducible, male-specific CYP2C11 
is regulated by STAT5 as well as liver nuclear factors (Park & Waxman, 
2001). STAT5-DNA complexes are formed in male rats but not in female 
rats. The CYP2C11 STAT5 site is flanked by a HNF3 consensus sequence, 
and HNF3β can suppress GH-inducible STAT5b tyrosine phosphorylation 
and thereby also CYP2C11 expression (Park & Waxman, 2001). 
 
STAT5b is a transcription factor, which responds to sexually dimorphic 
GH release. When GH binds to the GH-receptor, the GH-receptor-
associated tyrosine kinase (JAK2) is activated. JAK2 in turn phosphorylates 
tyrosine in the cytoplasmic domain of the GH-receptor at multiple sites, 
generating docking sites for STAT5b which is activated and dimerizes 
(Waxman & O'Connor, 2006). The activated complex translocates from the 
cytosol into the nucleus and induces transcription of the target gene 
(Waxman  et al., 1995). STAT5b undergoes repeated activation in direct 
response to successive GH pulses in adult male rats, while the activation of 
STAT5b is desensitized by the more persistent pattern of GH exposure in 
females (Tannenbaum et al., 2001). 
 
The genetic regulation of the human CYP2C genes is partially known. In 
the promotor regions of CYP2C8, CYP2C9 and CYP2C19, binding sites 
for the constitutive androgen receptor (CAR-RE) have been identified 
(Chen et al., 2003; Dvorak et al., 2003; Gerbal-Chaloin et al., 2002) and in 
all three genes the CAR-RE binds CAR as well as the pregnane X receptor 
(PXR). Glucocorticoid-responsive elements have also been identified in the 
promotor regions of CYP2C8, CYP2C9 (Gerbal-Chaloin  et al., 2002; 
Dvorak et al., 2003) and CYP2C19 (Chen et al., 2003). CYP2C9 appears to 
be a primary glucocorticoid-responsive (GR) gene, which could also be 
induced through CAR/PXR activation (Gerbal-Chaloin et al., 2002), while 
CYP2C19 may be upregulated equally by CAR/PXR and GR (Chen et al., 
2003). 
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The overall aims of this thesis were to examine differences in cytochrome 
P450 metabolism in commonly used mouse strains and to characterize a 
transgenic humanized CYP2C18 and CYP2C19 mouse model and explore 
the usefulness of this model in giving a more human-like metabolism in 
pharmacokinetic and toxicological studies. 
 
The specific aims of this thesis were: 
 
•  To study differences between commonly used mouse strains and 
genders regarding cytochrome P450 activities and protein levels. 
 
•  To characterize a heterozygous CYP2C18 and CYP2C19 gene-
addition mouse to obtain information regarding clinical status, 
clinical pathology and anatomical pathology. 
 
•  To characterize a heterozygous CYP2C18 and CYP2C19 gene-
addition mouse to obtain information regarding gene expression, 
enzyme expression and incorporation of the transgene segment. 
 
•  To elucidate sexually dimorphic gene expression observed in the 
CYP2C18 and CYP2C19 gene-addition mouse with main emphasis 
on GH and androgen effects on mRNA expression and CYP2C19 
promoters. 
  21  22Materials and Methods 
Animals 
Mice (Paper I) 
In paper I, livers from five different commonly used mouse strains were 
analyzed. The strains analyzed were CBA, C57BL/6, 129/SvJ, NMRI and 
CD1. In addition a crossbreed mouse (C57BL/CBA) and a transgenic 
mouse (Muta
TMMouse) were analyzed. The CBA, C57BL/6, C57BL/CBA 
and 129/SvJ strains were all 8 weeks old at organ sampling, the NMRI mice 
were 4-5 weeks, the Muta
TMMouse were 12 weeks and finally the CD1 
mice were 24 weeks old. Liver microsomes from both males and females 
(except Muta
TMMouse where only males were available) were prepared. 
Livers were pooled for each strain and sex separately. Pools prepared from 
CBA, C57BL/CBA and C57BL/6 mice contained 10 animals per gender; 
CD1 pools contained livers from five animals per gender. The 129/SvJ and 
NMRI pools were prepared from nine males and 10 females, each. The 
Muta
TMMouse pool contained 11 males. 
Mice (Paper II-IV) 
In papers II-IV, transgenic mice, heterozygous for the human CYP2C18 
and  CYP2C19 genes, and their wildtype littermates were used. The 
transgenic model was developed at AstraZeneca Transgenic Centre in 
Mölndal, Sweden. The model was generated by nuclear injection of a 
human bacterial artificial chromosome (BAC clone) RP11-466J14, which 
contains both complete CYP2C18 and CYP2C19 genes. In all studies with 
this mouse model the founders were genotyped using genomic DNA 
(gDNA) extracted from tail or ear biopsies. 
  23In paper II, six animals per group were examined from each gender and 
genotype. All mice were observed clinically one week prior to necropsy at 
an age of approximately 11 weeks old. During that week, clinical signs were 
recorded and the body weight gains and food consumptions were measured. 
Individual body weights were recorded four and six days before necropsy for 
males and three and six days before necropsy for females. Six males and six 
females from each genotype (wildtype and tg-CYP2C18 & 19) were 
examined. 
 
In paper III animals of different ages were used for the different 
experiments. For mRNA analysis, 6 males and 7 females were used, all 
being 26-31 weeks old. For the FISH analysis, two heterozygous mice were 
crossed and 13-day embryos were collected to obtain primary mouse 
embryonic fibroblasts. For S-mephenytoin activity measurements, liver 
microsomes from 9 weeks old transgenic and wildtype mice were used. Six 
wildtype mice and eight transgenic mice from each gender were used. For 
measuring omeprazole metabolism, liver microsomes from 12 weeks old 
male wildtype (n=10) and transgenic (n=4) mice were used. Finally, when 
measuring protein expression, the same liver microsomes from 12 weeks old 
male mice were used as for the omeprazole analysis. Due to limitations in 
material availability, microsomes from four transgenic males were still used, 
but microsomes were only available from nine (out of ten) wildtype mice. 
 
In paper IV, two separate in-life studies were conducted. In the first 
study, transgenic male mice were castrated or underwent sham surgery at 3 
weeks of age. Female transgenic mice had a testosterone capsule or a placebo 
capsule implanted subcutaneously at an age of 3 weeks. All transgenic mice 
and their wildtype littermates were euthanized at an age of 11 weeks. All 
groups contained five animals, except the sham surgery group, which 
contained only four mice. In the second in-life study, adult (8-11 weeks old) 
male transgenic mice had a GH capsule or a placebo capsule inserted 
subcutaneously. The transgenic males (GH and placebo) were euthanized 
four or seven days post surgery. Male wildtype and female transgenic mice 
were used as controls. All groups contained 4-6 individuals. 
  24Genotyping (Paper II-IV) 
In papers II-IV, the mice were genotyped to ascertain the possession of the 
inserted human genes. In paper II, the possession of CYP2C18 and 
CYP2C19, as well as the 3’ and 5’ ends of the inserted BAC segment, was 
investigated. In papers III and IV, only the possession of the CYP2C19 gene 
was investigated and IL-2 was used as an internal control. Genomic DNA 
was extracted from ear or tail biopsies using commercial kits (DNeasy 
Tissue, Qiagen) or established protocols (Laird et al., 1991; Sambrook & 
Russel, 2001). The primers transcripts were amplified by PCR and the 
amplified products visualized on ethidium/agarose gels. 
mRNA expression (Paper III and IV) 
Total RNA from liver, kidney, small intestine, brain (papers III and IV) 
heart and lung (paper III) was extracted using commercially available kits 
(Qiagen) and the purity and concentration of the extracted RNA was 
assessed spectrophotometrically. The integrity of the RNA was visualized via 
formaldehyde-agarose electrophoresis. The RNA was reverse transcribed 
into cDNA before real time analysis. The primer pairs used for the 
amplification of CYP2C18 and CYP2C19 w e r e  d e s i g n e d  t o  s h o w  l o w  
homology with endogenous murine Cyp2c isoforms using a multiple 
sequence alignment (ClustralW). Combinations of murine hypoxanthine 
guanine phosphoribosyltransferase (HPRT), glyceralaldehyde-3-phosphate 
dehydrogenase (GAPDH) and β-actin were used as normalization factors for 
the various analyses. The quantitative expression of the CYP2C18 and 
CYP2C19 genes, as well as the murine endogenous Cyp2c29, Cyp2c37-40, 
Cyp2c54-55 and Cyp2c70 were determined by real time PCR. In paper IV. 
a large number of known sexually dimorphic genes (Holloway et al., 2006) 
were used as positive controls. The amplified products were measured 
directly by monitoring the fluorescence of the reporter dye, FAM (TaqMan 
analyses), or monitoring the increase in SYBR®Green bound to the 
amplified double-stranded DNA (SYBR analyses) 
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Microsomes were prepared by homogenization of livers (paper I and III) and 
kidneys (paper III) followed by centrifugation for 10 minutes at 10 000 g. 
The supernatants were then centrifuged and washed twice at 105 000 g for 
70 minutes. The washed microsomes were suspended in 50 mM potassium 
phosphate buffer (0.4 mg/g original weight) and stored at approximately -
80ºC until use. The liver microsomes were used for both protein 
determination (western blots) and activity measurements. 
 
In papers I and III, western blot analyses were performed on microsomal 
proteins separated by SDS-polyacrylamide gel electrophoresis. The proteins 
were transferred to PVDF membranes. The membranes were incubated 
with primary antibodies (see Table 1 for paper I). In paper III, an α-
hCYP2C antipeptide targeted against the four C-terminal amino acids of 
human CYP2C8/9/18/19 and murine Cyp2c70 was used. Secondary 
antibodies were applied after washing of the membranes. The membranes 
were again washed and the complexes were detected with ECL
TM detection 
kit and Hyperfilm-ECL (paper I) or with horseradish peroxidase conjugation 
and SuperSignal West Pico chemiluminescent substrate (paper III). 
 
Table 1. Antibodies used for protein detection in Paper I 
Primary antibody (polyclonal) 
Antirat 1A1  Antirat 2C11 
Antirat 1A2  Antirat 2C13 
Antihuman 1B1  Antirat 2D1 
Antihuman 2A6  Antirat 2D4 
Antirat 2B1  Antihuman 2D6 
Antihuman 2B6 and Antirat 2B1/2  Antirat 2E1 
Antirat 2C6  Antirat 3A 
Antihuman 2C8/9/19 and Antirat 2C12  Antirat 4A 
In paper III kidney microsomes and Huh-7 and COS-7 cells transiently 
transfected with recombinant CYP2C18 were also analyzed using western 
blot with the same α-hCYP2C antipeptide. 
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In paper I, classical marker substrates for human CYP enzymes were 
incubated with the mouse liver microsomes and the activities of the 
microsomes were measured with fluorescence, high performance liquid 
chromatography (HPLC) or liquid chromatography/mass spectrometry 
(LC/MS). For substrates and detection systems used, see Table 2. 
 
In paper I, the total CYP content, CYP reductase activity and NADPH 
oxidation were also measured spectrophotometrically. In the case of total 
CYP content, the concentration was measured from the CO-difference 
spectra between 450 and 490 nm of dithionite-reduced samples. The CYP 
reductase activity was determined as the reduction of cytochrome C at 550 
nm and 30ºC, in 0.33 M potassium phosphate buffer. The rate of NADPH 
oxidation was determined by continuously recording the absorbance at 
340nm (loss of reduced NADPH) at 37˚C, in a cuvette with microsomes. As 
reference, a sample without added NADPH was used. 
 
In paper III, S-mephenytoin hydroxylation was measured using the same 
method as in paper I, with the exceptions that the incubation times were 0-
20 minutes, the final methanol concentration was 1% and the reactions were 
stopped by the addition of one volume of acetonitrile. R-omeprazole was 
used as an additional probe substrate for CYP2C19 activity in paper III. The 
rate of hydroxylation of R-omeprazole was measured using HPLC. 
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Activity measured 
Commonly used as probe 
for (human CYP) 
Initial 
probe 
conc. 
Microsomal 
protein 
conc.  
Reaction 
time 
Final 
solvent 
conc. 
Termination/stop 
solution 
Analytical method 
  (μM)  (mg/ml)  (min)   (ml)  Column  Mobile phase  Flow rate 
(ml/min) 
Detection 
System 
Phenacetin O-deethylation 
(CYP1A2) 
1 0.50 5  ---  ACN  Symmetry  C18 
50x2.1 mm, 3.5 μm 
Gradient 2-95% 
ACN in 0.1% HAc 
0.4 LC/MS 
Coumarin 7-hydroxylation 
(CYP2A6) 
4 0.25 10  ---  Fluorescence 
recorded in real time 
--- ---  ---  Ex./Em.: 
390/460 nm 
7-Ethoxy-4-triflouromethyl-
coumarin deethylation 
(CYP2B6) 
10 0.20 15  0.2% 
ACN 
Fluorescence 
recorded in real time 
---- ---  ---  Ex./Em.: 
405/535 nm 
Diclofenac 4’ -hydroxylation 
(CYP2C9) 
5  0.25  10  ---  ACN: Glacial acetic 
acid (47:3) 
Symmetry C8 
50x2.1 mm, 3.5 μm 
Gradient 2-95% 
ACN in 0.1% HAc 
0.4 LC/MS 
Bufuralol 1´-hydroxylation 
(CYP2D6) 
5 0.25 10  ---  ACN  Symmetry  C18 
50x2.1 mm, 3.5 μm 
Gradient 2-95% 
ACN in 0.1% HAc 
0.4 LC/MS 
Dextromethorphan O-
demethylation (CYP2D6) 
5  0.50  15  ---  70% perchloric acid  Symmetry C8 30 mM ammonium 
acetate: ACN 75:25 
1.0 Fluoresc.Ex./Em.: 
270/312 nm 
Chlorzoxazone 6-
hydroxylation (CYP2E1) 
40 0.50 15  0.6mM 
KOH 
70% perchloric acid  LiChroCART 
250-4 
Gradient 30-60% 
ethanol 
0.8 UV  Absorbance: 
280 nm 
p-Nitrophenol O-
hydroxylation (CYP2E1) 
100  0.20  40  ---  0.6M perchloric acid  ---  ---  ---  VIS-photometry 
Abs.: 546 nm 
Testosterone 6-β-
hydroxylation (CYP3A4) 
80 0.50 30  0.4% 
DMSO 
ACN LiChroCART 
250-4 
Gradient 30-60% 
ethanol 
0.8  UV Abs.: 254 nm 
Lauric acid 12-hydroxylation 
(CYP4A) 
50  0.50  30  ---  ACN: 1M H3PO4 
(1:1) 
AquaSil C18 
30x2.1mm, 3μm 
Gradient 2-80% 
ACN in 0.1% HAc 
0.3 LC/MS 
Amiodarone disappearance  1  0.50  10  1% ACN  ACN  Atlantis 
30x2.1mm, 3μm 
0.1% formic acid  0.35  LC/MS/MS 
Paclitaxel disappearance  10  0.50  10  0.1% 
Ethanol 
ACN Atlantis 
30x2.1mm, 3μm 
0.1% formic acid  0.35  LC/MS/MS 
S-Mephenytoin 
disappearance and 4-
hydroxylation (CYP2C19) 
10 0.50 40  0.1% 
Methanol 
ACN Symmetry  C8 
50x2.1 mm, 3.5 μm 
Gradient 2-80% 
ACN in 0.1% HAc 
0.4 LC/MS 
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In paper II, multiple clinical pathology parameters (both haematology and 
blood chemistry) were investigated, see Table 3. In general, haematology 
parameters were analyzed using standard methodologies and commercially 
available kits were used when analyzing blood chemistry parameters. Bone 
marrow differentials were determined by flow cytometry. 
 
Table 3. Parameters measured in clinical pathology 
Haematology Blood  chemistry 
Basophils Albumin 
Erythrocytes Albumin/globulin  ratio 
Eosinophils Alkaline  aminotransferase 
Hematocrit Alkaline  phosphatase 
Haemoglobin Aspartate  aminotransferase 
Large unstained cells  Bilirubin (total) 
Leucocytes Calcium 
Lymphocytes Cholesterol 
Mean corpuscular haemoglobin  Creatinine 
Mean corpuscular haemoglobin concentration  Glucose 
Mean red cell volume  Potassium 
Monocytes Sodium 
Neutrophils Total  protein 
Platelets Triglycerides 
Red cell distribution width  Urea 
Reticulocytes  
Anatomical pathology (Paper II) 
Most tissue specimens were fixed in 10% buffered formalin; while testicles 
and epididymides were fixed in Bouin’s solution and eyes were fixed in 
MFAA (methanol, formalin, acetic acid). All preserved tissues (Table 4) were 
embedded in paraffin according to standard methods, stained with 
haematoxylin and eosin (HE) and evaluated histologically. 
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Adrenal glands  Kidneys 
Aorta (thoracic)  Liver with gallbladder 
Salivary gland (parotid, 
submaxillary and lingual) 
Sternum Lungs  Seminal  vesicles 
Brain Skeletal  muscle 
Brown fat deposit
s Skin 
Cervix 
Lymph node 
(mandibular and 
mesenteric)  Spleen 
Epididymides  Spinal cord (lumbar and cervical) 
Epididymal fat deposit 
Nerves (sciatic and 
optic)  Stomach 
Esophagus  Ovaries  Testes 
Eyes Pancreas  Thymus 
Femur/femoro-tibial joint  Parathyroid glands  Thyroid glands 
Harderian gland  Pituitary gland  Tongue 
Heart Prostate  gland-ventral  Trachea 
Urinary bladder  Retriperitoneal fat 
deposit  Uterus 
Intestines (duodenum 
jejunum, ileum, colon, 
caecum, rectum)   Vagina 
Fluorescent in Situ Hybridisation (Paper III) 
In situ hybridization (Figure 6) was performed to detect the localization of 
the CYP2C18/19 BAC segment used for producing the transgenic mice 
used in papers II-IV. Primary mouse fibroblasts were obtained from 13 days 
old mouse embryos. After culturing of the cells, chromosomes were 
obtained according to standard cytogenetic techniques. DNA from the BAC 
clone was labelled in parallel with biotin-dUTP or digoxin-dUTP. Labelled 
BAC DNA was applied to chromosomes fixed to a slide and DNA and 
chromosomes were denaturated together. Hybridization was performed 
overnight at 37ºC. For probe detection, antidigoxigenin antibodies coupled 
with rhodamin/avidin coupled with a fluorescent dye (fluorescein 
isothiocyanate) were added to the slide. Slides were stained with DAPI (4', 
6-Diamidino-2-Phenylindole) and the hybridization signals were analyzed. 
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Figure 6. In situ hybridization. Picture modified from 
http://en.wikipedia.org/wiki/Fluorescent_in_situ_hybridization. 
Electrophoretic Mobility Shift Assay (Paper IV) 
In paper IV, nuclear extracts prepared from mouse livers were used in 
Electrophoretic Mobility Shift Assays (EMSAs) to find the regulatory 
elements for the sexually dimorphic expression of CYP2C18 and CYP2C19 
in the humanized mouse model used. Wildtype and mutated STAT5b 
oligonucleotides were labelled with 
32P using T4 polynucleotide kinase and 
[γ-
32P] ATP. Binding reactions were carried out in a HEPES buffer with 
glycerol, Poly (dI-dC)-Poly (dI-dC), the double stranded radiolabeled 
probes and mouse nuclear protein. For supershift assays, liver nuclear 
extracts were first incubated with STAT5b antibodies on ice for 45 minutes. 
Competition experiments were carried out with 100-fold excess of 
unlabelled double stranded oligonucleotides. DNA was resolved on 4% non-
denaturating polyacrylamide gels, which were dried and scanned using a 
phosphoimager. 
Statistical Analysis (Paper I-IV) 
In paper I, the statistical calculations were performed with SigmaStat 
software. Spearman’s rank correlation coefficients were calculated for the 
relationship between activities and western blot densities, as well as for co-
correlation analyses between activity-activity and western blot-western blot 
pairs. 
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arbitrary cut offs were added. When comparing the average activity/protein 
expression for one strain with the pooled average activity/expression for the 
other mouse strains, a strain was considered to be different from the others 
when the average was less than half, or more than twice that of the average 
of the pool. Similarly, when all mouse strains investigated were pooled and 
compared with literature data, the results were considered to differ from 
literature data if the average of the pool was less than half, or more than 
twice that, of the value obtained from the literature. 
 
In paper II, all comparisons between wildtype and transgenic mice were 
conducted with a t-test. 
 
S-Mephenytoin and R-omeprazole metabolism between microsomes 
from mice with different genotypes (wildtype and transgenic) were 
compared using the Mann-Whitney test in paper III. 
 
In paper IV, all genotype, treatment and gender comparisons of mRNA 
levels were performed with a t-test.  
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Mouse strain and gender differences in cytochrome P450 
activities and protein levels (Paper I) 
The first paper in the thesis focuses on differences in CYP metabolism 
between strains commonly used in different stages of medical research and 
drug development. The strains investigated were CBA, C57BL/6, 129/SvJ. 
NMRI, CD1 and in addition a transgenic mouse strain (Muta
TMMouse) was 
included. The CBA strain is used in transgenic mouse development as a 
breeding strain, usually crossbred with C57BL. Both the CBA and the 
C57BL strains have relatively good reproductive performances (Les, 1980), 
and the C57BL/CBA crossbreed give large litter-sizes which is an advantage 
when aiming for offspring with altered genome. The larger the littersizes, 
the larger is the probability for obtaining pups with an altered genome. The 
C57BL strain is probably the most widely used mouse strain in research 
(http://www.informatics.jax.org/external/festing/mouse/docs/C57BL.shtml), 
both in industry and in academia. The 129 strain is the easiest strain from 
which embryonic stem cells, used for development of knock-out mice, can 
be obtained (Seong et al., 2004). The NMRI strain is often used in efficacy 
tests (Kreppel et al., 1995; Tingstedt et al., 2007; Lamberty et al., 2002), 
while the CD1 strain often is used for drug safety and toxicity tests (D'Cruz 
et al., 2004; Stern et al., 2005; Satoh et al., 2006). Muta
TMMouse is a 
transgenic mouse model used for detecting mutations in vivo (Szegedi et al., 
2000; Myhr, 1991). 
 
Although different mouse strains are used in pharmaceutical 
development, little consideration has been given to the metabolism 
differences that may occur between the strains and cause differences in test 
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occurred and evaluate the importance of these, if any. In addition a literature 
search was made to compare mouse metabolism with human metabolism for 
the same substrates. 
 
Differences in both protein expression and activities for the substrates 
used were shown, but the exact identity of the proteins detected and the 
metabolism they perform was sometimes difficult to assess. It was difficult to 
positively identify proteins detected in Western blots, since no mouse 
specific cytochrome P450 antibodies were available. Also, no mouse specific 
cytochrome P450 substrates to use in activity measurements were found. 
 
In four of the five strains examined, male mice metabolized phenacetin (a 
human CYP1A2 substrate) faster than females from the same strain and this 
correlated with the protein expression detected with rat CYP1A2 
antibodies. Coumarin (a human CYP2A6 substrate) was most efficiently 
metabolized in the 129/SvJ strain. Diclofenac (a human CYP2C9 substrate) 
was generally metabolized to diclofenac 4’-hydroxylase faster in female than 
in male mice. The rate of paclitaxel disappearance (paclitaxel 6α-
hydroxylation is a marker activity for human CYP2C8) was higher in males 
than in females, except for the 129/SvJ strain where the rate of metabolism 
was the opposite, with females having the higher metabolism. Two human 
CYP2D6 marker substrates, i.e. bufuralol 1’-hydoxylation and 
dextromethorphan  O-demethylation, were used in activity measurements 
and female mice metabolized both substrates faster than male mice. Two 
marker activities for human CYP2E1 were used in the activity studies, i.e. 
chlorzoxazone 6-hydroxylation and p-nitrophenol  O-hydroxylation. 
Chlorzoxazone was hydroxylated, at position 6, twice as fast in CBA females 
as in CBA males, but no other evident gender differences were observed in 
the other strains investigated. Both the chlorzoxazone and p-nitrophenol 
activities correlated well with the protein detected by rat CYP2E1 
antibodies, and it is likely that mouse Cyp2e1 is responsible for the two 
activities measured. Testosterone 6β-hydroxylation was faster in females than 
in males for all strains studied, except for C57BL6 where the activities were 
approximately the same in both genders. The testosterone 6β-hydroxylation 
also correlated well with one of the bands detected with antibodies against 
rat-CYP3A. Cyp3a11 has previously been shown to catalyze testosterone 
6β-hydroxylation (Yanagimoto et al., 1992), and the mRNA expression of 
Cyp3a11 is independent of sex in C57BL mice (Jarukamjorn et al., 2006; 
Down  et al., 2007), while the information from other strains is scarce. 
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2003), is expressed in a sex-dependent manner, with women having higher 
average enzymatic activity than men. The 7-ethoxy-4-triflouromethyl-
coumarin deethylation (7-EFC, human CYP2B6 substrate), amiodarone 
disappearance (where the amiodarone N-demethylation is a marker for 
human CYP2C8 metabolism), S-mephenytoin disappearance (where S-
mephenytoin 4-hydroxylation is a marker for human CYP2C19) and lauric 
acid 12-hydoxylation (marker for human CYP4A) did not show any 
consistent differences between strains or genders. 
 
The results from the first paper clearly show large differences in CYP 
protein levels as well as in CYP-dependent metabolism. Although the 
proteins detected and the CYP enzymes metabolizing the different substrates 
could not be positively identified, it was clear that the differences could 
cause differences in test results. In addition to the strain differences 
identified, quite a few enzymes showed sex-dependent expression and 
several activities indicated sex-dependent metabolism. These results are 
interesting since many early studies in pharmaceutical development are only 
conducted in males. 
Differences between mouse and human cytochrome P450 
activities (Paper I) 
Mouse liver microsomes had higher metabolic rates for bufuralol 
1’-hydroxylation and dextromethorphan O-demethylation (both human 
CYP2D6 marker substrates) than human liver microsomes (literature data). 
Human liver microsomes on the other hand had higher metabolic rates for 
coumarin 7-hydroxylation (marker for human CYP2A6), diclofenac 
4’-hydroxylation (marker for human CYP2C9) and testosterone 
6β-hydroxylation (marker for human CYP3A4) than mouse liver 
microsomes. Interestingly, more than 50% of the drugs on the market today 
are metabolized by members from these four subfamilies (Williams et al., 
2004; Wienkers & Heath, 2005) and drugs have been developed in animal 
models where these relatively large differences in drug metabolism may exist 
between humans and the model used. 
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CYP2C19 gene-addition mouse (Paper II) 
Better animal models and better prediction of human toxicity are always 
desired and new models are continuously being developed. Once such 
models are developed, it is important to find out if the animals are healthy or 
if the phenotypes are connected to adverse effects that may shorten the 
lifespan, affect the health of the animals or in any other way make the animal 
models unsuitable. 
 
When a phenotypic characterization was performed on the heterozygous 
CYP2C18 and CYP2C19 gene-addition mouse, no pathological changes 
were observed. Despite the fact that many clinical- and anatomical 
pathology parameters were measured, only a few differences between 
wildtype and heterozygous mice were observed. 
 
The average brain was shown to have somewhat reduced weight in the 
humanized mouse as compared to wildtype littermates in both genders. The 
adrenal weight and brown fat deposits were reduced in transgenic males 
compared to controls, while the heart weight was increased. The spleens of 
female transgenic mice weighed less than spleens from controls. When 
analyzing clinical pathology parameters, transgenic males were found to have 
higher blood glucose levels and female transgenes had lower levels of blood 
triglycerides than wildtype littermates. The reasons for these organ weight 
and blood chemistry alterations were not further investigated, but some of 
the differences could possibly be attributed to the role of members in the 
cytochrome P450 2c subfamily in arachidonic acid (Wang et al., 2004; 
Alkayed et al., 1996) and lipid metabolism (Stewart & Strother, 1999). 
 
Despite the few alterations observed between wildtype and CYP2C18 
and CYP2C19 gene-addition mice, the heterozygous transgenic mice were 
considered to be viable and healthy animals. Although the mice were 
healthy, it remains to be evaluated if this animal model could be considered 
a better model than currently available mice for examination of metabolism 
of drugs that are mainly CYP2C19 substrates. 
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(Paper III) 
The human CYP2C18 and CYP2C19 genes were shown to be inserted into 
region C1 of murine chromosome 2 in the mouse genome. The number of 
incorporated segments was determined using a real time PCR approach 
based on existing methodologies (De Preter et al., 2002) utilizing 
quantification of the human and murine IL-2 genes as standards, (Hoebeeck 
et al., 2007), and the number of tandem copies was determined to be 
approximately 12. An example (using simple whole numbers) of how to 
estimate the copy number is given in Figure 7. 
 
 
Figure 7. The mouse CYP2C19 copy numbers were calculated relative to human gDNA 
samples, using the following equation: (1+E)
-ΔCt 2C19/(1+E)
-ΔCt IL2, where E is the efficiency of 
the PCR reaction (in this example set to 100%), ΔCt 2C19 and ΔCt IL-2 are the differences 
in mean CYP2C19/IL-2 threshold cycles between mouse and human gDNA samples (in this 
example set to –3 and 0 respectively). In this example, the mouse CYP2C19 gene copy 
number would be: 2
3/2
0=8. Since the human sample contains two copies of the gene, while a 
heterozygous mouse only a single copy, the total number per mouse haploid gene would be 
2x8=16. 
 
It is not unusual to have a high number of transgene copies incorporated 
(Xing et al., 2007) when using the pronuclear injection technique. In the 
CYP2D6 transgene (Corchero et al., 2001), 5 ± 1 copies per haploid 
genome were found and approximately 5 gene copies were found in the 
homozygous CYP3A4 model (Granvil et al., 2003). Two copies have been 
found in two humanized CYP2E1 founders and 20 copies were found in 
another CYP2E1 founder (Morgan et al., 2002). 
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(Paper III and IV) 
Differences in CYP2C19 expression between the sexes at the mRNA (liver, 
kidney, heart), protein (liver) and activity (liver) levels are shown in papers 
III and IV. Differences in CYP2C18 mRNA expression are also evident 
between the sexes in liver and kidney. No specific antibodies could be 
found for western blot analysis, while the primers used for mRNA analyses 
were considered to be specific and gave distinct differences between the 
genotypes. When trying to determine CYP2C19 protein levels from 
western blots (no CYP2C18 protein could be detected), the antibody used 
cross-reacted with murine Cyp2c70. Similarly, when activities for R-
omeprazole and S-mephenytoin were measured, the metabolism was carried 
out by more than one enzyme, as shown by the fact that metabolites were 
also detected in wildtype littermates. Despite this cross reactivity, an increase 
in the total level of immunoreactive protein (CYP2C19/Cyp2c70) was 
evident (42% increase) in transgenic male mice as compared to wildtype 
controls. Similarly, an increased hydroxylation of omeprazole and 
mephenytoin was observed in transgenic males compared to wildtype 
littermates. The increase in metabolism and protein expression observed in 
the transgenic mice compared to wildtype control mice was nevertheless 
considered to be low, bearing in mind the high number of CYP2C19 copies 
inserted (~12) in the genome. A low rate of metabolism performed by 
inserted cytochrome P450 segments in transgenic CYP mice has also been 
described for other models (Gonzalez, 2007; Felmlee et al., 2008), and 
compensatory downregulation of the murine Cyp enzymes has been 
suggested. No statistically significant increase in the metabolism of R-
omeprazole or S-mephenytoin substrates could be detected in female 
CYP2C18/CYP2C19 humanized mice compared to their wildtype 
littermates, explained by the absence of expression of these genes in female 
liver (see below). 
 
Sex differences in the expression of CYP2C family members have 
previously been shown in the rat where the male-specific CYP2C11, and 
the female-specific CYP2C12,  are the major isoenzymes. Expression of 
CYP2C11 can be down-regulated by continuous administration of GH, 
while the same gene can be up-regulated in response to intermittently 
administered GH (Mode et al., 1998). In hamsters, Cyp2c27 has been shown 
to be male predominant in the liver (Sakuma et al., 1994). In paper IV we 
show that the mouse Cyp2c37, Cyp2c38, Cyp2c39 and Cyp2c40 genes also 
show a sexually dimorphic mRNA expression with all four genes being 
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isoenzyme expression have been shown in rat, mouse and hamster, no 
corresponding unambiguous dimorphic expression of CYP2C enzymes has 
been observed in human livers. 
 
Both GH (Waxman & O'Connor, 2006) and gonadal hormones 
(MacGeoch et al., 1985; Janeczko et al., 1990; van den Berg et al., 1996) 
have been shown to be essential in the differentiation and expression of 
many sexually dimorphic CYPs. “Feminization” of male mice was 
accomplished using two different methods in paper IV. The first method 
was to castrate male mice prior to puberty and the second was to administer 
GH continuously (using a subcutaneously implanted micro-osmotic pump) 
for 4 or 7 days. Wildtype males release GH in a pulsatile manner while 
females have a more constant release (Kato et al., 1986; Waxman & 
O'Connor, 2006). Both the performed attempts to feminize male mice, i.e. 
castration and continuous GH administration, were successful in the sense 
that castration and GH treatment feminized in part or completely the 
CYP2C18 and CYP2C19 expression in liver and kidney (an example of test 
results from GH administration is given in Figure 8. 
 
Figure 8. Effect on hepatic CYP2C18 and CYP2C19 mRNA expression by continuous 
administration of GH to heterozygous CYP2C18/CYP2C19 male mice. As control groups, 
placebo treated heterozygous CYP2C18/CYP2C19 males and untreated heterozygous 
CYP2C18/CYP2C19 females were used. 
 
  39In addition, female mice were ”masculinized” by administrating 
testosterone (using subcutaneously implanted 60-day release pellets) in a 
constant manner. The testosterone administration to female mice had the 
most prominent “masculinizing” effect on CYP2C19 in the kidney. 
 
Neither CYP2C18 nor CYP2C19 showed sexually dimorphic expression 
in brain, or in small intestine and no response to the hormonal treatments 
was observed in these organs. It is quite interesting though that the mRNA 
expression of both CYP2C18 and CYP2C19 is relatively high in the small 
intestine compared with in the liver (paper III), especially for CYP2C19 
where the expression in the small intestine is higher than in liver for female 
heterozygous mice. 
Genetic regulation of CYP2C18 and CYP2C19 (Paper IV) 
The regulatory mechanisms for the sexually dimorphic expression of the 
inserted human CYP2C18 and CYP2C19 genes are investigated in paper 
IV. Pulsatile GH secretion is known to stimulate translation of STAT5b and 
it has been suggested that STAT5b is the responsible transcription factor, 
regulating the sexually dimorphic expression of CYP2C11 and CYP2C12 in 
rats (Gebert et al., 1997; Kaufhold et al., 2002). There is also a close 
relationship between GH and other steroids by feedback mechanisms within 
the hypothalamic-pituitary-target organ axis. Gonadal steroid imprinting 
during the neonatal period influence the sex-dependent GH profiles in 
plasma that emerge at puberty (Waxman et al., 1985; Jansson et al., 1985). 
Although a STAT5b binding site was identified in the promotor region of 
CYP2C19, no binding to that region could be identified in EMSA studies 
(Figure 9). However, other proteins may interfere with binding of STAT5b 
to the identified promotor region and other promotor regions could also be 
responsible for the sexually dimorphic expression of the inserted genes. 
  40 
Figure 9. Electrophoretic mobility shift assay. Oligonucleotides for a putative wildtype (wt) 
and mutated (mut) STAT 5b as well as a control STAT5b sequence were labelled with [γ-
32P] ATP. Nonradiolabelled control competitor (100x) and STAT5b antibodies were 
incubated with nuclear extract at 4°C for 45 minutes (cold competition), followed by a 15 
minutes preincubation at 37°, whereafter radioactively labelled oligonucleotides were added 
and incubated for another 15 minutes at 37°C. NE: Nuclear Extract. 
  41Use of humanized CYP2C mice as drug safety models (general 
comments) 
Quite a few humanized models have been generated and characterized 
today, i.e. mice expressing CYP1A1/CYP1A2 (Cheung et al., 2005a), 
CYP2C18/19 (Löfgren et al., 2008), CYP2E1 (Cheung et al., 2005b), 
CYP2D6 (Corchero et al., 2001), CYP3A4 (Granvil et al., 2003; van 
Herwaarden et al., 2005) and CYP3A7 (Li et al., 1996). Although all these 
models contain human CYP genes, many of them suffer from drawbacks as 
safety and toxicity models. Compensatory mechanisms in the mouse Cyp 
expression may occur, and although parts of the human promotor regions 
are incorporated, the inserted genes are shown to be under mouse hormonal 
control. The inserted genes may show species specific expression, for 
example the CYP2C18/CYP2C19 model studied in this thesis has a clearly 
sexually dimorphic expression although there is no proof for CYP2C18 and 
CYP2C19 having sex-dependent expression in humans. These facts raise the 
question whether these models are more appropriate as safety models than 
conventional wildtype mice. Maybe they are more suitable for studying 
genetic regulation and expression of the human genes and increase our 
understanding of species specific (hormonal) regulation. To avoid a 
compensatory mechanism performed by murine subfamily members, knock-
out models and gene-swap models (i.e. human genes replacing the murine 
subfamily counterparts) could be a way forward. 
  42General conclusions 
•  Sex and strain differences in cytochrome P450 mRNA levels, 
protein expression and metabolism are common for murine enzyme 
families involved in drug metabolism (CYP1, CYP2 and CYP3). 
 
•  The humanized CYP2C18/CYP2C19 gene addition mice 
investigated are considered to be healthy, viable animals that could 
possibly be used in drug safety testing and investigation of the 
hormonal regulation of CYP2C18 and CYP2C19. 
 
•  The humanized CYP2C18/CYP2C19  gene addition mouse 
investigated shows a sexually dimorphic expression of the inserted 
genes. CYP2C18 and CYP2C19 mRNA levels and S-mephenytoin 
metabolism are much higher in liver from male transgenic mice than 
in female transgenic mice. 
 
•  The mRNA expression of CYP2C18 and CYP2C19 was decreased 
in livers from castrated male transgenic mice and male transgenic 
mice treated with continuous exogenous growth hormone as 
compared to untreated transgenic male mice. The mRNA 
expression of CYP2C18 and CYP2C19 was increased in female 
transgenic mice treated with testosterone compared to untreated 
transgenic female mice. 
  43  44Future research 
•  Investigate the regulatory mechanisms behind the sexually 
dimorphic expression of CYP2C18 and CYP2C19 
 
No STAT5b binding could be identified in the promotor region of 
CYP2C19 i n  E M S A  s t u d i e s .  I t  w o u l d  b e  o f  i n t e r e s t  t o  i d e n t i f y  a n d  
investigate putative STAT5b binding sequences in the promotor region of 
CYP2C18. It would also be of interest to investigate other nuclear receptors 
in the promotor regions of CYP2C18 and CYP2C19 for possible gender 
differences. Possible nuclear receptors to examine in EMSA studies could be 
hepatocyte nuclear factors, which have been shown to be involved in the 
regulation of rat CYP2C11 and CYP2C12. Other important nuclear 
receptors of interest are the constitutive androgen receptor, the pregnane X 
receptor and the glucocorticoid receptor, all of which have been shown to 
be involved in CYP2C19 expression in humans. 
 
•  Distribution of the inserted CYP2C18 and CYP2C19 genes 
 
Organ weight alterations between transgenic and wildtype mice were 
observed in the brain, heart, spleen, adrenal gland and brown fat deposits. 
No further investigations to elucidate these differences were performed. It 
would be of interest to study the mechanisms behind these alterations. 
Immunohistochemistry could show distributions of the inserted genes within 
these tissues. Is the expression more intense in some specific cell types? This 
could hopefully give some information when investigating the organ weight 
alterations. 
 
  45•  Use of the humanized CYP2C18/19 transgenic mouse in 
safety assessment 
 
Would this mouse model be better than conventional wildtype mice for 
drug safety testing? It would be of great interest to evaluate this model as a 
safety model, by administering known human CYP2C18 and CYP2C19 
substrates, for example omeprazole or diazepam. However, in order to be a 
useful model it is considered important to make a Cyp2c knockout model 
and crossbreed our transgene with these null mice in order to get a model 
that is reasonably well humanized with respect to the metabolism of human 
CYP2C19 substrates. 
 
•  To further develop, and investigate, the CYP2C knock out 
model 
 
Within AstraZeneca's CYP2C disease model project, attempts were made 
to develop a knockout model completely devoid of the mouse Cyp2c cluster 
without success. It would be of major interest to investigate why no such 
model could be developed. Is the Cyp2c cluster too large/too important to 
be deleted? The embryonic stem cells are viable and chimeras survive but no 
germline transmission occurs. Why is that? At what stage do the embryos die 
in utero? 
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  59  60Populärvetenskaplig sammanfattning 
Läkemedel som finns tillgängliga utvecklas och förbättras kontinuerligt och 
numera kan vi behandla sjukdomar som förut var livshotande och obotliga. 
Idag är det också allt mer vanligt med läkemedel som är riktade mot olika 
organ och individanpassade. För att i möjligaste mån undvika biverkningar 
och sidoeffekter är det väsentligt att veta vad som händer med läkemedlet 
när det kommer in i kroppen. Bieffekter är inte alltid beroende av mängden 
läkemedel som tillförs, de kan också bero på patientens mat- och 
dryckesvanor, om patienten röker eller om patienten använder flera 
läkemedel. 
 
I modern läkemedelsutveckling används djurmodeller för att undersöka 
hur läkemedel tas upp och utsöndras ur kroppen, och från dessa försök drar 
man slutsatser om förväntade effekter på människa. Tolkningen av resultaten 
från dessa studier kan dock vara svåra då det finns stora skillnader mellan 
djurmodeller och människa, men också mellan individer. Olika djurslag har 
olika nivåer av de ämnen som bryter ned läkemedel, s.k. enzymer. För vissa 
av enzymerna ses också skillnader mellan könen. Det är viktigt att känna till 
skillnader i enzymnivåer mellan arter, individer och kön för att kunna 
undvika oönskade effekter då läkemedlen ges till människa. 
 
Under de senaste årtiondena har möss blivit allt vanligare som 
djurmodeller inom läkemedelsindustrin, dels som modell i 
säkerhetstestningar av läkemedel ämnade för människa, men också som 
modelldjur för olika sjukdomar. Till exempel finns det möss som har en 
ökad tendens att utveckla olika cancerformer, och på dessa djur kan man 
prova olika behandlingar för att se om antalet tumörer och/eller deras storlek 
minskar. Trots att möss används allt mer flitigt inom forskning och 
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enzymnivåer mellan möss och människor. 
 
Läkemedel avlägsnas ifrån kroppen genom metabolism 
(ämnesomsättning/omvandling), vanligtvis till en mer vattenlöslig form som 
sedan kan lämna kroppen via urin eller galla. Hur snabbt läkemedlet 
avlägsnas från kroppen är starkt beroende av hur snabbt det omsätts. 
Metabolismen, tillsammans med hur snabbt läkemedlet tas upp ifrån tarmen, 
bestämmer vilken koncentration av läkemedlet man har i kroppens olika 
organ. 
 
Omsättningen av läkemedel och andra ämnen som kommer in i kroppen 
delas traditionellt upp i två delsteg. Det första steget (Fas I) uträttas av de så 
kallade cytochrom P450 enzymerna, som exempelvis introducerar en 
syreatom i läkemedlet. Reaktionen gör vanligtvis läkemedlet mer 
vattenlösligt och dessutom kan läkemedlet lättare genomgå nästa steg (Fas II) 
i metabolismen. I Fas II binds en kroppsegen substans, som till exempel ett 
socker, till läkemedlet vilket gör det än mer vattenlösligt, och kan ännu 
lättare utsöndras via urin eller galla. 
 
Kombinationen av Fas I och Fas II reaktioner anses generellt utgöra 
avgiftningsreaktioner, men det råder inget tvivel om att dessa processer 
ibland kan ge upphov till mellanprodukter som är giftigare eller mer 
cancerframkallande än ursprungsmolekylen. Ibland kan dessa reaktioner 
också ge upphov till mellanprodukter som är mer aktiva som läkemedel än 
det ursprungliga läkemedel som intagits. 
 
Fas I steget utgörs som sagt av de reaktioner som uträttas av de så kallade 
cytokrom P450 enzymerna, som är en grupp bestående av flera hundra 
enzymer som skiljer sig åt både i uppbyggnad och genom vilken typ av 
läkemedel/substanser som de föredrar att omvandla. Den så kallade 
cytokrom P450 2C (CYP2C) subfamiljen av enzymer bidrar till 
omvandlingen av ungefär 30 % av de läkemedel som finns på marknaden 
idag. Hos människa består CYP2C subfamiljen av fyra medlemmar 
(CYP2C8, CYP2C9, CYP2C18 och CYP2C19) medan denna familj hos 
mus tillhör en av de mest komplexa, med så mycket som 15 medlemmar 
(Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c44, Cyp2c50, 
Cyp2c54, Cyp2c55, Cyp2c65, Cyp2c66, Cyp2c67, Cyp2c68, Cyp2c69 och 
Cyp2c70). 
  
  62Genetiskt modifierade möss blir också allt vanligare inom forskningen 
och det kan vara svårt att förstå att det bara är ca 35 år sedan som de första 
stegen togs för att utveckla transgena möss. Idag finns det två principiellt 
olika metoder för att genetiskt förändra möss. Den första metoden innebär 
att man för in det förändrade materialet i arvsanlaget som kommer från den 
manliga individen strax efter befruktning (pronukleär injektion, se bild 
nedan), medan man i den andra metoden för in arvsanlaget i några dagar 
gamla embryon genom användning av embryonala stamceller. Vid 
pronukleär injektion kan det tillförda genetiska materialet fastna var som 
helst i arvsanlaget, och ofta inkorporeras flera kopior av generna. 
 
Detta arbete handlar i stora delar om en musmodell där man använt sig av 
pronukleär injektion för att få en mus som förutom sina egna CYP enzymer 
även uttrycker de mänskliga enzymerna CYP2C18 och CYP2C19. 
 
I den första delstudien i avhandlingen undersöktes skillnader i nivåerna av 
musens egna CYP enzymer hos olika musstammar. I arbetet undersöktes 
också förekomsten av skillnader i enzymnivåer mellan könen. För vissa av 
enzymerna påvisades stora skillnader mellan de olika stammarna och hos vissa 
stammar tycktes en del CYP enzymer saknas helt. För en del enzymer sågs 
också stora könsskillnader, där vissa enzymer dominerar hos honor medan 
andra är specifika för hanar. 
 
I delstudierna två och tre påvisades vad som kännetecknar en transgen 
musstam som innehåller de humana CYP2C18 och CYP2C19 enzymerna. 
Delstudie två fokuserade på musstammens egenskapers in vivo, dvs. på de 
biologiska processer som sker i celler och vävnader i den levande musen. 
Den tredje delstudien fokuserade istället på hur stammen fungerar in vitro, 
dvs. biokemiska processer som sker i förenklade system, till exempel 
isolerade celler i en artificiell miljö som exempelvis ett provrör. 
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Från in vivo studierna drogs slutsatsen att den transgena musstammen är 
sund och frisk utan några påtagliga skillnader jämfört med normala, icke 
genetiskt modifierade, möss. Några få skillnader i organvikter och halter av 
ämnen, såsom glukos och fett i blodet, kunde dock påvisas. Skillnaderna var 
dock små och bedömdes inte påverka musen. 
 
Från studier av de biologiska processer som sker in vitro kunde det visas 
att mellan 11 och 13 kopior av det tillagda genetiska materialet hade 
inkorporerats i arvsanlaget. Det visades också att transgena hanar hade högre 
nivåer i lever och njure av så kallat mRNA för CYP2C18 och CYP2C19 än 
transgena honor. ”Messenger RNA” eller mRNA som det förkortas är den 
molekyl som överför genetisk information från arvsanlaget i cellkärnan till 
cytoplasman (se bild nedan), information som sedan används för att tillverka 
äggviteämnen (proteiner). 
 
Vid analyser av proteinmängder och även enzymaktivitet blev tolkningen 
av resultaten något mer komplicerade. Eftersom många CYP enzymer är 
mycket lika i sin uppbyggnad reagerar de ofta lika på de substanser som 
används för att identifiera ämnen i molekylärbiologiska analyser. Detta 
gjorde det svårt att avgöra om proteinerna som påvisades och aktiviteterna 
som uppmättes härrörde från de tillförda mänskliga CYP2C18 och 
CYP2C19 generna, eller från något av musens egna enzymer. Dock kunde 
en ökning av både proteinnivåer och enzymaktivitet påvisas i transgena 
hanar jämfört med ej genetiskt modifierade möss. 
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I den fjärde och sista delstudien undersöktes könsskillnaderna som 
upptäcktes i delstudie tre djupare. Hanmöss gjordes mer feminina på två 
olika sätt, dels genom kastration innan de kommit upp i puberteten, dels 
genom att de tillfördes tillväxthormon (GH) kontinuerligt. På de flesta 
djurslag, men speciellt uttalat på gnagare, frisätts GH olika hos hanar och 
honor. Hanar utsöndrar GH i pulser med höga nivåer följt av perioder med 
nästan ingen utsöndring alls, honor däremot har en mer kontinuerlig 
utsöndring av GH med endast små fluktuationer i koncentration. Honmöss 
gjordes också mera maskulina genom att de tillfördes testosteron från tre 
veckors ålder (före pubertet). Samtliga möss avlivades vid ca 11 veckors ålder 
(de anses då vara fullvuxna) och mRNA-nivåer för dels CYP2C18 och 
CYP2C19 samt några av musens egna CYP2C enzymer undersöktes in vitro. 
Båda behandlingarna på transgena hanmöss (kastration samt GH behandling) 
gav ett mer feminint uttryck av båda CYP2C18 och CYP2C19 i lever och 
njure, där enzymnivåerna var lägre än i obehandlade möss. 
Testosteronbehandling av transgena honmöss gav inte lika stort utslag, men 
nivåerna av mRNA för både CYP2C18 och CYP2C19 i lever och njure, 
ökade hos dessa jämför med obehandlade honor. Nivåerna av musens 
Cyp2c37, Cyp2c38, Cyp2c39 och Cyp2c40 enzymer uppvisade också ett 
könsspecifikt uttrycksmönster, men här var nivåerna omvända mot de som 
observerades för CYP2C18 och CYP2C19, dvs. nivåerna var högre i honor 
än i hanar. Även musens egna Cyp enzymer svarade på de genomförda 
behandlingarna genom att kastrerade och GH behandlade hanar fick mer 
feminint uttryck och testosteronbehandlade honor fick mer maskulint 
uttryck. 
 
Sammanfattningsvis konstaterades att det finns stora stam- och 
könsskillnader i uttryck av cytokrom P450 hos mus. I den transgena 
musmodell som undersöks i delstudierna två, tre och fyra, uppvisar de 
inkorporerade  CYP2C18 och CYP2C19 segmenten ett könsspecifikt 
uttryck med högre nivåer av mRNA och protein i hanar än i honor trots att 
arvsanlaget är detsamma för båda könen. Detta könsspecifika uttryck kan 
påverkas genom kastration och GH behandling av hanar samt av 
testosteronbehandling av honor. Den transgena musen anses vara livskraftig 
och frisk och kan förhoppningsvis hjälpa till att förstå skillnader i 
läkemedelsomsättning mellan mus och människa. Den kan möjligtvis även 
anses vara en bättre mus att använda vid läkemedelstestning av substanser 
som omsätts av CYP2C18 och CYP2C19 än traditionella försöksdjur. 
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